Published in Transplantation on July 27, 2002
Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol (2004) 1.26
Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl (2009) 0.79
Challenges of recurrent hepatitis C in the liver transplant patient. World J Gastroenterol (2014) 0.77
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation (2010) 4.00
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev (2010) 2.70
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation (2013) 2.43
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS (2003) 1.78
Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog (2007) 1.29
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother (2006) 1.28
Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis (2003) 1.28
Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis (2008) 1.23
How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol (2005) 1.21
Analysis of the human cytomegalovirus genomic region from UL146 through UL147A reveals sequence hypervariability, genotypic stability, and overlapping transcripts. Virol J (2006) 1.13
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis (2003) 1.10
The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis (2011) 1.10
Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol (2006) 1.08
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog (2013) 1.05
Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol (2013) 1.04
Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis. Transplantation (2010) 1.02
Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis (2010) 1.01
Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci (2002) 0.99
Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J Clin Virol (2008) 0.97
Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol J (2009) 0.94
Human cytomegalovirus UL97 kinase and nonkinase functions mediate viral cytoplasmic secondary envelopment. J Virol (2011) 0.92
Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res (2011) 0.91
Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. Antimicrob Agents Chemother (2011) 0.91
The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. Antiviral Res (2011) 0.91
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol (2006) 0.91
Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. Antimicrob Agents Chemother (2013) 0.89
Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility. J Virol (2014) 0.87
Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice. Virol J (2006) 0.85
Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. Antimicrob Agents Chemother (2013) 0.85
HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M. J Clin Virol (2004) 0.84
Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. Antiviral Res (2011) 0.84
Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation. Hepatology (2005) 0.84
Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am (2010) 0.83
Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol (2002) 0.82
Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am (2010) 0.82
Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis. J Infect Dis (2002) 0.81
Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D. J Med Virol (2009) 0.81
DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun (2003) 0.79
Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs. Liver Transpl (2003) 0.79
Absence of activation of CMV by blood transfusion to HIV-infected, CMV-seropositive patients. Transfusion (2003) 0.75